Advertisement

The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover

      This paper is only available as a PDF. To read, Please Download here.

      Abstract

      This study examines the effect of nicotinic acid (1 g t.d.s.) on serum Lp(a) concentration in a group of patients with type II hyperlipidaemia selected on the basis of a plasma Lp(a) concentration greater than 30 mg/dl. Reductions in total cholesterol, triglyceride, LDL-cholesterol and Lp(a) were 16.3%, 25.5%, 23.7% and 36.4%, respectively, with an increase in HDL cholesterol of 37.3%. The reduction in Lp(a) concentration did not correlate with any other lipoprotein changes. In order to establish the mechanism of the fall in Lp(a) concentration, in vivo turnover of autologous Lp(a) was studied in three subjects before and whilst taking nicotinic acid. The fractional catabolic rate in Lp(a) was unaltered in the subjects on therapy, indicating that nicotinic acid did not increase catabolism of Lp(a) but decreased the synthetic rate. Since nicotinic acid was poorly tolerated we examined the effect of acipimox, an analogue of nicotinic acid on lipoproteins using a placebo controlled double-blind crossover design in a group of hyperlipidaemic patients again selected with plasma Lp(a) concentration greater than 30 mg/dl. Acipimox was better tolerated than nicotinic acid but the percentage changes in lipoprotein concentrations were smaller.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Armstrong V.W.
        • Cremer P.
        • Eberle E.
        • Manke A.
        • Schulze F.
        • Wieland H.
        • Kreuzer H.
        • Siedel D.
        The association between serum Lp(a) concentrations and angiographically assessed coronary atherosclerosis.
        Atherosclerosis. 1986; 62: 249
        • Scanu A.
        • Lawn R.
        • Berg K.
        Lipoprotein(a) and atherosclerosis.
        Ann. Intern. Med. 1991; 115: 209
        • Boerwinkle E.
        • Menzel H.J.
        • Kraft H.G.
        • Utermann G.
        Genetics of the quantitative Lp(a) lipoprotein trait. III. Contribution of Lp(a) glycoprotein phenotype to normal lipid variation.
        Hum. Genet. 1989; 82: 73
        • Lackner C.
        • Boerwinkle E.
        • Leffert C.
        • Rahmig T.
        • Hobbs H.
        Molecular basis of apolipoprotein (a) isoform size heterogeneity as revealed by pulsed-field gel electrophoresis.
        J. Clin. Invest. 1991; 87: 2153
        • Feely J.
        • Barry M.
        • Keeling P.W.N.
        • Weir D.G.
        • Cooke T.
        Lipoprotein(a) in cirrhosis.
        Br. Med. J. 1992; 304: 545
        • Webb A.
        • Plant M.
        • Reaveley D.
        • O'Donnell M.
        • Luck V.
        • O'Connor B.
        • Seed M.
        • Brown E.
        Lipid and Lipoprotein (a) concentrations in renal transplant patients.
        Nephrol. Dial. Transplant. 1992; 7: 636
        • Black I.W.
        • Wilken D.E.L.
        Decreases in apolipoprotein (a) after renal transplantation: Implications for lipoprotein (a) metabolism.
        Clin. Chem. 1992; 38: 353
        • Knight B.
        • Perombelon N.
        • Soutar A.
        • Wade D.
        • Seed M.
        Catabolism of lipoprotein(a) in familial hypercholesterolaemic subjects.
        Atherosclerosis. 1991; 87: 227
        • Crook D.
        • Sidhu M.
        • Seed M.
        • O'Donnell M.
        • Stevenson J.C.
        Lipoprotein Lp(a) levels are reduced by danazol, an anabolic steroid.
        Atherosclerosis. 1992; 92: 41
        • Albers J.J.
        • Taggart H.M.
        • Applebaum-Bowden D.
        • Haffner S.
        • Chesnut C.H.
        • Hazzard W.R.
        Reduction of lecithin-cholesterol acyltransferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanazolol.
        Biochim. Biophys. Acta. 1984; 795: 293
        • Gurakar A.
        • Hoeg J.M.
        • Kostner G.
        • Papadopoulos N.M.
        • Brewer Jr., H.B.
        Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment.
        Atherosclerosis. 1985; 57: 293
        • Carlson L.A.
        • Hamsten A.
        • Asplund A.
        Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid.
        J. Intern. Med. 1989; 226: 271
        • Sirtori C.R.
        • Gianfranchesi G.
        • Sitori M.
        • Bernini F.
        • Descovich G.
        • Montaguti U.
        • Fuccella M.
        • Musatt L.
        Reduced triglyceridaemia and increased high density lipoprotein cholesterol levels after treatment with acipimox, a new inhibitor of lipolysis.
        Atherosclerosis. 1981; 38
        • O'Kane M.J.
        • Trinick T.R.
        • Tynan M.B.
        • Trimble E.R.
        • Nicholls D.P.
        A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
        Br. J. Clin. Pharmacol. 1992; 33: 1
        • Kostner G.M.
        • Avogaro P.
        • Cazzolato G.
        • Marth E.
        • Bittolo-Bon G.
        • Qunici G.B.
        Lipoprotein Lp(a) and the risk for myocardial infarction.
        Atherosclerosis. 1981; 38: 51
        • Grundy S.M.
        Dietary treatment of hyperlipidaemia.
        in: Hypercholesterolemia and Atherosclerosis. Pathogenesis Prevention. Churchill Livingstone, New York1987: 169-193
        • Burstein M.
        • Schlonick H.R.
        • Morfin R.
        Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions.
        J. Lipid. Res. 1970; 11: 583
        • Friedewald W.T.
        • Levy R.I.
        • Fredrickson D.S.
        Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge.
        Clin. Chem. 1972; 18: 499
        • Labeur C.
        • Rosseneu M.
        • Henderson L.O.
        Results of two international surveys on Lp(a) measurementsx.
        (Abstract)in: 2nd International Conference of Lp(a), New Orleans1992: 83
        • Utermann G.
        • Menzel H.J.
        • Kraft H.G.
        • Duba H.C.
        • Kemmler H.G.
        • Seitz C.
        Lp(a) glycoprotein phenotypes.
        J. Clin. Invest. 1987; 80: 458
        • Bilheimer D.W.
        • Goldstein J.L.
        • Grundy S.M.
        • Brown M.S.
        Reduction in cholesterol and low density lipoprotein synthesis after portacaval shunt surgery in a pa tient with homozygous familial hypercholesterolaernia.
        J. Clin. Invest. 1975; 56: 1420
        • Matthews C.M.E.
        The theory of tracer experiments with 131I-labelled plasma proteins.
        Phys. Med. Biol. 1957; 2: 36
        • Siegel S.
        Non-parametric Statistics for Behavioural Sciences.
        Macgraw-Hill-Kogakusha, 1956
        • Dixon W.J.
        • Brown M.B.
        • Engelman L.
        • France J.W.
        BMDP Statistical Software.
        University of California, 1983
        • Fuccella L.M.
        • Goldangia G.
        • Lovisolo P.
        • Maggie E.
        • Musatti L.
        • Mandelli V.
        • Sirtori C.R.
        Inhibition of lipolysis by nicotinic acid and acipimox.
        Clin. Pharmacol. Ther. 1980; 28: 790
        • Canner P.J.
        • Berge K.G.
        • Wenger N.K.
        • Stamler J.
        • Friedman L.
        • Prineas R.J.
        • Friedewald W.
        Fifteen year mortality in Coronary Drug Prevention Study pa tients: Long term benefit with niacin.
        J. Am. Coll Cardiol. 1986; 8: 1245
        • Brown G.
        • Albers J.
        • Fisher L.
        • Schaefer S.
        • Lin J.
        • Kaplan C.
        • Zhao X.
        • Bisson B.
        • Fitzpatrick V.
        • Dodge H.
        Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apolipoprotein B.
        N. Engl. J. Med. 1990; 323: 1289